Rezultati - Brian Elliott
- Showing 1 - 3 results of 3
-
1
-
2
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study od Martin Hutchings, Rogier Mous, Michael Roost Clausen, Peter Johnson, Kim Linton, Martine E.D. Chamuleau, David John Lewis, Anna Sureda, David Cunningham, Roberto S Oliveri, Brian Elliott, Dena DeMarco, Ada Azaryan, Christopher Chiu, Tommy Li, Kuo-mei Chen, Tahamtan Ahmadi, Pieternella J. Lugtenburg
Izdano 2021Artigo -
3
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial od Catherine Thiéblemont, Tycel Phillips, Hervé Ghesquières, Chan Y. Cheah, Michael Roost Clausen, David Cunningham, Young Rok, Tatyana Feldman, Robin Gasiorowski, Wojciech Jurczak, Tae Min Kim, David John Lewis, Marjolein van der Poel, Michelle Poon, Mariana Cota Stirner, Nurgul Kilavuz, Christopher Chiu, Menghui Chen, Mariana Sacchi, Brian Elliott, Tahamtan Ahmadi, Martin Hutchings, Pieternella J. Lugtenburg
Izdano 2022Artigo
Iskalna orodja:
Sorodne teme
Medicine
Astrobiology
Cancer research
Internal medicine
Lymphoma
Oncology
Refractory (planetary science)
Adverse effect
Antibody
Biology
Bispecific antibody
Clinical trial
Immunology
Law
Medical education
Medical research
Mentorship
Monoclonal antibody
Open label
Open label study
Pathology
Physics
Political science
Psychology
Publication
Publish or perish
Publishing
Scholarship
Statistician